Clinical Trials Browser

INDUSTRY × Recurrence × 90 days × Clear all

NCT06634589 2026-03-18

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07480213 2026-03-18

DART-NK-SCLC

Phase 1/2 Recruiting

Recurrence, Small Cell Lung Carcinoma

NCT07480954 2026-03-18

DUAL-OV-CAR-NK

Phase 1/2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06189391 2026-03-17

MK-1045-001

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07156565 2026-03-17

ATLAS

Phase 1 Recruiting

Recurrence, Sarcoma

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07297979 2026-03-16

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Phase 1 Recruiting

Recurrence, Sarcoma, Ewing

NCT03460977 2026-03-13

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT06425991 2026-03-13

MajesTEC-10

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT06149286 2026-03-06

OLYMPIA-5

Phase 3 Recruiting

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Phase 1 Recruiting

Bites and Stings, Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT04416984 2026-03-04

ALPHA2

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06846606 2026-03-03

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06984328 2026-03-03

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

Melanoma, Recurrence

NCT07166094 2026-03-03

RAINFOL-03

Phase 3 Recruiting

Recurrence, Endometrial Neoplasms

NCT03939026 2026-03-02

ALPHA

Phase 1 Completed

Lymphoma, Lymphoma, Follicular, Recurrence

NCT05714345 2026-03-02

EXPAND

Phase 2 Terminated

2 enrolled 8 charts

Lymphoma, Recurrence

NCT06173518 2026-03-02

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05815160 2026-02-27

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Active not recruiting

Recurrence, Small Cell Lung Carcinoma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT02926690 2026-02-25

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT04279847 2026-02-25

LIMBER

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Phase 1/2 Recruiting

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT07116616 2026-02-24

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT07123454 2026-02-24

Lumi-NHL

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT05537740 2026-02-23

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05124912 2026-02-20

REMASTer: REcurrent Brain Metastases After SRS Trial

Phase NA Recruiting

Brain Neoplasms, Neoplasm Metastasis, Recurrence

NCT05527184 2026-02-20

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Phase 1 Active not recruiting

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Recurrence, Endometrial Neoplasms

NCT05888493 2026-02-20

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06051695 2026-02-20

EVEREST-2

Phase 1/2 Recruiting

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT07424833 2026-02-20

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT04619056 2026-02-19

First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Phase 1 Completed

Recurrence, Sarcoma

NCT03686124 2026-02-18

ACTengine

Phase 1/2 Recruiting

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence